NCT07731191 · RECRUITING

Digital Solutions for Predicting the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors

This trial is testing an AI-powered digital tool that analyzes risk factors to predict whether someone with early memory concerns is on a biological path toward Alzheimer's or another dementia. It uses an app for patients and a web platform for clinicians. This is a Phase NA study, meaning it is a device validation study rather than a drug trial — the goal is to see how well the prediction tool performs, not to test a treatment.

You may qualify if

  • Male or female subjects aged more than 18 years at the time of signing the informed consent form;
  • Subjects with MCI or SCD who, at the time of their first visit, did not have a clinical diagnosis of dementia (MMSE ≥ 24);
  • Smartphone user.

You're excluded if

  • Age younger than that stated in the inclusion criterion;
  • Inability to understand.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-07-28

View full record on ClinicalTrials.gov

All APOE4 clinical trials